Aura Biosciences, Inc. (AURA) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
2.82
↑+23% vs avg
5yr avg: 2.30
30Y Low1.6·High3.3
ROE
↓
-73.5%
↑-59% vs avg
5yr avg: -46.1%
30Y Low-89%·High-34%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
AURA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Aura Biosciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $412M | $329M | $408M | $351M | $314M | $496M | — | — |
| Enterprise Value | $369M | $287M | $395M | $330M | $214M | $348M | — | — |
| P/E Ratio → | -3.64 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 2.82 | 2.40 | 2.69 | 1.55 | 1.61 | 3.26 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
AURA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
AURA Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -73.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -73.5% | -73.5% | -46.0% | -36.3% | -33.8% | -41.1% | -88.6% | -78.7% |
| ROA | -60.3% | -60.3% | -39.7% | -31.9% | -30.6% | -38.7% | -75.1% | -65.3% |
| ROIC | -72.4% | -72.4% | -42.0% | -42.6% | -91.3% | -851.2% | -10124.3% | — |
| ROCE | -70.8% | -70.8% | -46.9% | -37.3% | -32.9% | -41.0% | -88.2% | -78.1% |
AURA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $60M exceeds total debt of $17M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.13 | 0.12 | 0.09 | 0.11 | 0.01 | 0.00 | 0.00 |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.31 | -0.09 | -0.10 | -0.51 | -0.97 | -0.90 | -1.05 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -2711.54 | -7402.00 | -4839.00 |
Net cash position: cash ($60M) exceeds total debt ($17M)
AURA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Aura Biosciences, Inc.'s current ratio of 8.15x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 18.76x to 8.15x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.15 | 8.15 | 10.77 | 18.76 | 18.81 | 20.90 | 6.94 | 5.42 |
| Quick Ratio | 8.15 | 8.15 | 10.77 | 18.76 | 18.81 | 20.90 | 6.94 | 5.42 |
| Cash Ratio | 7.85 | 7.85 | 10.13 | 18.30 | 18.06 | 20.27 | 6.54 | 5.28 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
AURA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Aura Biosciences, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $60M | $50M | $40M | $30M | $29M | $29M | $2.9B |
Peer Comparison
Compare AURA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 AURAYou | $412M | -3.6 | — | — | — | — | -73.5% | -72.4% | — |
 OCUL | $2B | -6.3 | — | — | 87.3% | -521.0% | -54.9% | — | — |
 RCKT | $300M | -1.4 | — | — | — | — | -60.3% | -62.4% | — |
 ADVM | $96M | -0.7 | — | — | 100.0% | -13915.9% | -189.8% | -124.2% | — |
 REPL | $733M | -2.9 | — | — | — | — | -62.6% | -51.9% | — |
 IMVT | $7B | -12.1 | — | — | — | — | -64.8% | — | — |
 NUVL | $9B | -21.1 | — | — | — | — | -36.7% | -32.5% | — |
 SGHT | $279M | -6.9 | — | — | 86.2% | -48.0% | -50.7% | -274.4% | — |
 LNTH | $7B | 30.7 | 16.9 | 19.2 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
 AGEN | $137M | -970.6 | — | — | 29.6% | -18.0% | — | — | — |
 IMCR | $1B | -54.6 | — | — | 97.9% | -11.3% | -7.1% | -17.2% | — |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
What if you invested $1,000 in AURA 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in AURA be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs AURA Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationAURA vs OCUL — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Ocular Therapeutix, Inc..
Compare NowAURA — Frequently Asked Questions
Quick answers to the most common questions about buying AURA stock.
What is Aura Biosciences, Inc.'s P/E ratio?
Aura Biosciences, Inc.'s current P/E ratio is -3.6x. This places it at the 50th percentile of its historical range.
What is Aura Biosciences, Inc.'s ROE?
Aura Biosciences, Inc.'s return on equity (ROE) is -73.5%. The historical average is -56.8%.
Is AURA stock overvalued?
Based on historical data, Aura Biosciences, Inc. is trading at a P/E of -3.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.